tetano
Editor, Senior Moderator
J Infect Dis. 2013 Mar 7. [Epub ahead of print]
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
Source
Department of Pediatrics, Golisano Children's Hospital, Upstate Medical University, Syracuse NY USA.
Abstract
Background. Two antigenically distinct influenza B lineages have co-circulated since 2001, yet trivalent influenza vaccines (TIV) contain one influenza B antigen, meaning lineage-mismatch with the vaccine is frequent. We assessed a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages versus TIV in healthy children aged 3-17 years.Methods. Children were randomized 1:1:1 to receive QIV or one of two TIVs (either B/Victoria or B/Yamagata lineage) (N=2738). Hemagglutination-inhibition assays were performed 28-days after one or two doses in primed and unprimed children, respectively. Immunological non-inferiority of QIV versus TIV against shared strains, and superiority against alternate-lineage B strains was based on GMTs and seroconversion rates. Reactogenicity and safety were also assessed. NCT01196988Results. Non-inferiority against shared strains and superiority against alternate-lineage B strains was demonstrated for QIV versus TIV. QIV was highly immunogenic; seroconversion rates were 91.4%, 72.3%, 70.0%, and 72.5% against A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, respectively. Reactogenicity and safety of QIV was consistent with TIV.Conclusions. QIV versus TIV showed superior immunogenicity for the additional B strain without interfering with immune responses to shared strains. QIV may offer improved protection against influenza B in children compared with current trivalent vaccines.
PMID:
23470848
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23470848
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
Source
Department of Pediatrics, Golisano Children's Hospital, Upstate Medical University, Syracuse NY USA.
Abstract
Background. Two antigenically distinct influenza B lineages have co-circulated since 2001, yet trivalent influenza vaccines (TIV) contain one influenza B antigen, meaning lineage-mismatch with the vaccine is frequent. We assessed a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages versus TIV in healthy children aged 3-17 years.Methods. Children were randomized 1:1:1 to receive QIV or one of two TIVs (either B/Victoria or B/Yamagata lineage) (N=2738). Hemagglutination-inhibition assays were performed 28-days after one or two doses in primed and unprimed children, respectively. Immunological non-inferiority of QIV versus TIV against shared strains, and superiority against alternate-lineage B strains was based on GMTs and seroconversion rates. Reactogenicity and safety were also assessed. NCT01196988Results. Non-inferiority against shared strains and superiority against alternate-lineage B strains was demonstrated for QIV versus TIV. QIV was highly immunogenic; seroconversion rates were 91.4%, 72.3%, 70.0%, and 72.5% against A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, respectively. Reactogenicity and safety of QIV was consistent with TIV.Conclusions. QIV versus TIV showed superior immunogenicity for the additional B strain without interfering with immune responses to shared strains. QIV may offer improved protection against influenza B in children compared with current trivalent vaccines.
PMID:
23470848
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23470848